Methylglyoxal Modified Proteins antibody

Catalog No. ABIN2192148

The Mouse Monoclonal anti-Methylglyoxal Modified Proteins antibody (Clone MGO-1) (ABIN2192148) specifically detects Methylglyoxal Modified Proteins in IHC (p), WB and IA. The antibody is reactive with Human samples.

Quick Overview for Methylglyoxal Modified Proteins antibody (ABIN2192148)

Target: Methylglyoxal Modified Proteins

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB), Immunoassay (IA)

Clone: MGO-1

Product Details

Cross-Reactivity (Details): Cross reactivity: Multispecies : Yes

Sterility: 0.2 μm filtered

Isotype: IgG1

Application Details

Application Notes: For immunohistochemistry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting.

Restrictions: For Research Use only

Handling

Buffer: PBS, containing 0.1 % bovine serum albumin and 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.

Target Details

Target: Methylglyoxal Modified Proteins

Background: The monoclonal antibody MGO-1recognizes human MGO modified proteins. Methylglyoxal (MGO) is an endogenous product of glucose metabolism. Increased production and accumulation of methylglyoxal (MGO), as well as increased modification of proteins by glycoxidation, are hallmarks of aging and diabetes. MGO was shown to modify proteins and to contribute to the accumulation of damaged proteins that can be toxic to cells. A number of studies have shown that MGO levels are significantly elevated in patients with Type 2 Diabetes and correlates well with fasting plasma glucose and hemoglobin A1c (HbA1c) levels. Moreover, increased formation of the MGO is implicated in renal dysfunction and is known to be involved in the development of DN (diabetic nephropathy). Immunogen MGO-modified KLH